-+ 0.00%
-+ 0.00%
-+ 0.00%

Bernstein Maintains Outperform on Beam Therapeutics, Raises Price Target to $41

Benzinga·01/21/2026 15:28:30
Listen to the news
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $37 to $41.